← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 CareDx CDNA $3.32B	174	-8	-4%	$921M
27	27 Ultragenyx Pharmaceutical RARE $1.47B	173	+3	+2%	$2.51B
28	28 Precigen PGEN $2.46B	170	+8	+5%	$712M
29	29 Regenxbio RGNX $469M	168	-18	-10%	$1.04B
30	30 uniQure QURE $1.54B	159	+15	+10%	$1.26B
31	31 Fate Therapeutics FATE $228M	149	+13	+10%	$1.15B
32	32 Pacific Biosciences PACB $553M	148	-2	-1%	$607M
33	33 Vericel Corp VCEL $2.06B	137	0	0%	$588M
34	34 Intellia Therapeutics NTLA $1.59B	136	-8	-6%	$589M
35	35 Voyager Therapeutics VYGR $126M	131	+6	+5%	$528M
36	36 Standard BioTools LAB $252M	125	-10	-7%	$296M
37	37 Adaptive Biotechnologies ADPT $3.88B	117	+6	+5%	$2.5B
38	NSTG 38 DELISTED NanoString Technologies, Inc. NSTG	113	-25	-18%	$841M
39	39 Atara Biotherapeutics ATRA $96.8M	112	-4	-3%	$833M
40	40 Lakefront Biotherapeutics American Depositary Shares LKFT $1.95B	111	+9	+9%	$1.29B
41	41 DELISTED Adverum Biotechnologies ADVM	99	+5	+5%	$267M
42	ATNX 42 DELISTED Athenex, Inc. Common Stock ATNX	99	+8	+9%	$526M
43	ATHX 43 DELISTED Athersys, Inc. Common Stock ATHX	96	-2	-2%	$43.5M
44	44 Lineage Cell Therapeutics LCTX $250M	96	-11	-10%	$63.2M
45	45 Allogene Therapeutics ALLO $456M	95	+1	+1%	$1.87B
46	46 Rocket Pharmaceuticals RCKT $256M	92	-4	-4%	$555M
47	47 10x Genomics TXG $9.13B	92	+92	–	$1.13B
48	48 Wave Life Sciences WVE $629M	88	-12	-12%	$634M
49	49 Krystal Biotech KRYS $9.55B	85	+9	+12%	$393M
50	50 Twist Bioscience TWST $8.82B	84	-1	-1%	$374M